Form 4: Avidity Biosciences Director Jean Jinsun Kim Receives Significant Equity Grant

Avidity Biosciences, Inc. director Jean Jinsun Kim was granted 6,692 restricted stock units and 10,034 stock options, aligning her interests with shareholders.

Summary

• Jean Jinsun Kim, a Director of Avidity Biosciences, Inc. (RNA), reported the acquisition of equity securities on June 10, 2025.
• The transaction included the acquisition of 6,692 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.
• Additionally, 10,034 Stock Options (Right to Buy) were acquired with an exercise price of $33.62 per share.
• Both the RSUs and stock options are scheduled to vest in full on the earlier of June 10, 2026, or the Issuer's 2026 annual meeting of stockholders, contingent upon Ms. Kim's continuous service to the Issuer.
• The stock options have an expiration date of June 9, 2035.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the equity grant aligns the director's interests with shareholders, which is generally viewed favorably. However, it's a routine compensation event and not indicative of significant operational news.

Positives

• The grant of restricted stock units and stock options to a director, Jean Jinsun Kim, aligns her long-term interests with those of the company's shareholders, incentivizing performance and commitment.
• The equity compensation package is a standard practice for retaining and motivating key board members in the biotechnology sector.

Risks

• The value of the granted RSUs and stock options is subject to the future performance of Avidity Biosciences' common stock, which carries inherent market and operational risks.
• Vesting of the equity is contingent on continuous service, meaning the director must remain with the company until the vesting date to realize the full benefit.

Future Outlook

The future outlook for the director's equity compensation is tied to the company's stock performance and her continued service through the vesting period, which is expected to occur by June 10, 2026, or the 2026 annual meeting of stockholders.

Industry Context

Equity grants to directors are a common form of compensation in the biotechnology and pharmaceutical industries, aiming to align the interests of board members with long-term shareholder value creation. This practice is consistent with industry standards for attracting and retaining experienced leadership.

Comparison to Industry Standards

• The use of RSUs and stock options for director compensation is a standard practice across the biotechnology sector, comparable to compensation structures at companies like Alnylam Pharmaceuticals (ALNY) or Sarepta Therapeutics (SRPT), which also utilize equity to incentivize long-term commitment.
• The specific number of units and options granted would typically be benchmarked against peer companies of similar market capitalization and stage of development, though this document does not provide comparative data for a detailed assessment.

Corporate Governance

Related Party Transactions

• The transaction involves an equity grant from Avidity Biosciences, Inc. to its director, Jean Jinsun Kim, which is a standard form of compensation for an insider.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with those of the shareholders, potentially leading to more focused decision-making aimed at increasing shareholder value.
• Employees: While not directly impacting employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The restricted stock units and stock options will vest based on the specified conditions (continuous service until June 10, 2026, or the 2026 annual meeting of stockholders).

Key Dates

Keywords

Avidity Biosciences, RNA, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSU, Stock Options, Director Compensation, Corporate Governance